Tissue informative cell-free DNA methylation sites in amyotrophic lateral sclerosis

C. Caggiano,M. Morselli,X. Qian,B. Celona,M. Thompson,S. Wani,A. Tosevska,K. Taraszka,G. Heuer,S. Ngo,F. Steyn,P. Nestor,L. Wallace,P. McCombe,S. Heggie,K. Thorpe,C. McElligott,G. English,A. Henders,R. Henderson,C. Lomen-Hoerth,N. Wray,A. McRae,M. Pellegrini,F. Garton,N. Zaitlen

DOI: https://doi.org/10.1101/2024.04.08.24305503

2024-04-10

Abstract:Cell-free DNA (cfDNA) is increasingly recognized as a promising biomarker candidate for disease monitoring. However, its utility in neurodegenerative diseases, like amyotrophic lateral sclerosis (ALS), remains underexplored. Existing biomarker discovery approaches are tailored to a specific disease context or are too expensive to be clinically practical. Here, we address these challenges through a new approach combining advances in molecular and computational technologies. First, we develop statistical tools to select tissue-informative DNA methylation sites relevant to a disease process of interest. We then employ a capture protocol to select these sites and perform targeted methylation sequencing. Multi-modal information about the DNA methylation patterns are then utilized in machine learning algorithms trained to predict disease status and disease progression. We applied our method to two independent cohorts of ALS patients and controls (n=192). Overall, we found that the targeted sites accurately predicted ALS status and replicated between cohorts. Additionally, we identified epigenetic features associated with ALS phenotypes, including disease severity. These findings highlight the potential of cfDNA as a non-invasive biomarker for ALS.

Genetic and Genomic Medicine

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to develop a new method, using methylation sites in cell - free DNA (cfDNA) as non - invasive biomarkers for Amyotrophic Lateral Sclerosis (ALS). Specifically, the research aims to:

1. **Identify tissue - specific methylation sites**: By combining molecular and computational techniques, select Tissue - Informative DNA Methylation Sites (TIMs) related to specific disease processes.
2. **Develop a capture protocol**: Design capture probes, select these TIMs, and perform targeted methylation sequencing.
3. **Utilize multi - modal information**: Use machine - learning algorithms to predict disease status and disease progression based on the methylation patterns of cfDNA.
4. **Verify the validity of the model**: Apply this method in two independent cohorts of ALS patients to verify its accuracy in predicting ALS status and replicating results.
5. **Explore ALS phenotype - related features**: Identify epigenetic features related to ALS phenotypes (such as disease severity).

Through these steps, the research hopes to demonstrate the potential application value of cfDNA as a non - invasive biomarker in ALS.